Research programme: IPL12 series - Inflazyme

Drug Profile

Research programme: IPL12 series - Inflazyme

Alternative Names: IPL 12a85ME; IPL12 series research programme - Inflazyme

Latest Information Update: 19 Jul 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Allergic rhinitis; Asthma

Most Recent Events

  • 29 Jun 2005 This programme is still in active development
  • 15 Apr 2005 Sanofi-aventis has terminated its licence for the IPL12 series of LSAIDs™
  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top